Expedition Therapeutics

About Expedition Therapeutics

Expedition Therapeutics is a biotech company focused on developing novel oral therapies for inflammatory and respiratory diseases, most notably a next‑generation DPP1 inhibitor (EXPD‑101) for chronic obstructive pulmonary disease (COPD). The firm aims to address neutrophilic inflammation, a key driver of lung tissue damage, and is advancing its lead candidate through Phase 2 trials with plans to expand into related neutrophil‑driven conditions.